-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SYD-4228 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SYD-4228 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SYD-4228 in Marginal Zone B-cell Lymphoma Drug Details: SYD-4228...
-
Product Insights
NewNet Present Value Model: Newron Pharmaceuticals SpA’s Evenamide
Empower your strategies with our Net Present Value Model: Newron Pharmaceuticals SpA's Evenamide report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewSchizophrenia – Drugs In Development, 2024
Empower your strategies with our Schizophrenia – Drugs In Development, 2024 report and make more profitable business decisions. Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech, and disorganized behavior. Risk factors include family history, age, drugs (psychoactive), and weakened immune system. Treatment includes antipsychotic medications. The Schizophrenia drugs in development market research report provide comprehensive information on the therapeutics under development for Schizophrenia, complete with...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niclosamide in Ulcerative Colitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Niclosamide in Ulcerative Colitis Drug Details:Niclosamide is under development for the treatment of ulcerative colitis, proctitis...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VAD-044 in Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VAD-044 in Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease)Drug Details:VAD-044 is under development for the treatment of hereditary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Priralfinamide in Neuropathic Pain (Neuralgia)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Priralfinamide in Neuropathic Pain (Neuralgia) Drug Details: Ralfinamide is under development for the treatment...
-
Sector Analysis
Parkinson’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast 2029
Parkinson’s Disease Market Report Overview The PD market size across the 7MM was valued at $3.4 billion in 2019 and will achieve a CAGR of more than 6% during 2019-2029. The growing aging population and the launches of several new pipeline products across the 7MM will drive market growth during the forecast period. Parkinson’s Disease Market Outlook, 2019-2029 ($ Billion) Buy Full Report to Get More Insights into the Parkinson’s Disease Market Forecast Download a Free Report Sample The PD...
-
Company Profile
Newron Pharmaceuticals SpA – Company Profile
Newron Pharmaceuticals SpA (Newron Pharmaceuticals) is a research-based biopharmaceutical company that focuses on the discovery, development, and commercialization of novel therapeutic drugs for the treatment of central nervous system disorders and pain. The company’s marketed the product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson's disease. Newton's other products in the pipeline include ralfinamide for neuropathic pain; sarizotan for Rett syndrome; and Evenamide (NW-3509) for the treatment of schizophrenia. The company has development and commercialization...
Add to Basket -
Product Insights
Parkinson’s Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Parkinson’s Disease Clinical Trials Market Report Overview In total there were 2,622 clinical trials conducted on Parkinson's Disease, as of February 2023, of which the majority of clinical trials were in Europe. The Parkinson’s Disease clinical trial market research report provides an overview of the clinical trials scenario. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 &...
-
Product Insights
Net Present Value Model: Evenamide
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Evenamide Drug Details Evenamide (NW-3509) is...